Multiple studies have shown superior survival benefits for anti‐PD‐1/PD‐L1 inhibitors plus chemotherapy compared to chemotherapy in NSCLC patients without EGFR or ALK alterations.8, 9, 10, 11. Here, EGFR is linked to non-small cell lung carcinoma.